Tag Archives: Avycaz

February, 2016

  • 24 February

    FDA Accepts and Grants Priority Review to Allergan’s Avycaz sNDA

    DUBLIN, Feb. 24, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) for AVYCAZ® (ceftazidime and avibactam). This filing will add important new clinical data to the current label …